Skip to main content
. 2022 Sep 15;36(10):e22514. doi: 10.1096/fj.202200765R

FIGURE 5.

FIGURE 5

Combinatorial Ara‐C/venetoclax treatment regimen augments metabolism of CNL to long‐chain ceramide metabolites. (A‐E). MOLM‐14 cells were treated with CNL 15 μM, Ara‐C 1.25 μM, venetoclax 50 nM alone or in combinations as indicated for 24 h, prior to lipid analyses. Shown are total ceramide levels (A), individual ceramide species (A‐C), ratios of the change in long‐chain C16‐ to very‐long‐chain C24:1‐ceramide (D), and levels of sphingosine and sphingosine‐1‐phosphate (E). N = 4–5, shown are means +/− SEM *p < .02 to vehicle; #p < .001 to CNL/Ara‐C/venetoclax (A); ^p < .005 to vehicle (E).